Fig. 1From: An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocolThe current regenerative medicine landscape. Compiled using Thomson Reuters Cortellis™ competitive intelligence software. Gene therapy candidates currently lead the Discovery phase, whilst most Launched drugs comprise tissue-engineered products (including skin substitutes). MSC: mesenchymal stem cell, AAV: adeno-associated virusBack to article page